BROMURO DE PANCURONIO PDF

Tolrajas Metronidazole The therapeutic efficacy of Pancuronium can be increased when used in combination with Metronidazole. Octaethylene glycol The therapeutic efficacy of Octaethylene glycol can be decreased when used in combination with Pancuronium. Beclomethasone dipropionate The risk or severity of myopathy and weakness can be increased when Pancuronium is combined with Beclomethasone dipropionate. Fenyramidol The risk or severity of adverse effects can be increased when Pancuronium is combined with Fenyramidol. Cupric sulfate The therapeutic efficacy of Cupric sulfate can be bromudo when used in combination with Pancuronium. Hexamethonium The therapeutic efficacy of Hexamethonium can be decreased when used in combination with Pancuronium.

Author:Gardak Tojazragore
Country:Slovenia
Language:English (Spanish)
Genre:Photos
Published (Last):17 November 2013
Pages:453
PDF File Size:1.64 Mb
ePub File Size:7.1 Mb
ISBN:316-1-22279-380-5
Downloads:77989
Price:Free* [*Free Regsitration Required]
Uploader:Sajas



Samule Carbenicillin The therapeutic efficacy of Pancuronium can be increased when used in combination with Carbenicillin. Mazindol The risk or severity of adverse effects can be increased when Mazindol is combined with Pancuronium.

Butriptyline The risk or severity pancuronnio adverse effects can be increased when Pancuronium is combined with Butriptyline. Metoclopramide The therapeutic efficacy of Pancuronium can bromurl decreased when used in combination with Metoclopramide. Dotarizine Dotarizine may increase the neuromuscular blocking activities of Pancuronium. Chlorphentermine The risk or severity of Tachycardia can be increased when Pancuronium is combined with Chlorphentermine.

Estradiol The risk or severity of adverse effects can be increased when Estradiol is combined with Pancuronium. Caroverine Caroverine may increase the neuromuscular blocking activities of Pancuronium.

Efavirenz The risk or severity of adverse effects can be increased when Efavirenz is combined with Pancuronium. Dacomitinib The risk or severity of adverse effects can be increased when Dacomitinib is combined with Pancuronium. Hydrocortisone The risk or severity of myopathy and weakness can be increased when Pancuronium is combined with Hydrocortisone. Carvedilol Pancuronium may increase the bradycardic activities of Carvedilol.

Nimesulide Nimesulide may increase the neuromuscular blocking activities of Pancuronium. Biperiden The therapeutic efficacy of Biperiden can be decreased when used in combination with Brokuro. Mebicar The risk or severity of adverse effects can be increased when Pancuronium is combined with Mebicar.

Alphacetylmethadol The risk or severity of adverse effects can be increased when Pancuronium is combined with Alphacetylmethadol. Hydrocortisone acetate The risk or severity of myopathy brpmuro weakness can be increased when Pancuronium is combined with Hydrocortisone acetate.

Nevirapine The risk or severity of adverse effects can be increased when Nevirapine is combined with Pancuronium. Fenthion The therapeutic efficacy of Pancuronium can be decreased when used in combination with Bromuri.

Gepefrine The risk or severity of Tachycardia can be increased when Pancuronium is combined with Gepefrine. Diphenidol The therapeutic efficacy of Diphenidol can be decreased when used in combination with Pancuronium.

Gallopamil Gallopamil may increase the neuromuscular blocking activities of Pancuronium. Nisoxetine The risk or severity of adverse effects can be increased when Pancuronium is combined with Nisoxetine. Landiolol Pancuronium may increase the bradycardic activities of Landiolol. Castor oil The therapeutic efficacy of Castor oil can be decreased when used in combination with Pancuronium.

Aminophylline The therapeutic efficacy of Pancuronium can be decreased when used in combination with Aminophylline. Brexpiprazole The risk or severity of adverse effects can be increased when Pancuronium is combined with Brexpiprazole. Fospropofol The risk or severity of adverse effects can be increased when Pancuronium is combined with Fospropofol.

Naronapride The risk or severity of adverse effects can be increased when Pancuronium is combined with Naronapride. Ciclesonide The risk or severity of myopathy and weakness can be increased when Pancuronium is combined with Ciclesonide. Ginkgo biloba The therapeutic efficacy of Pancuronium can be decreased when used in combination with Ginkgo biloba.

Metaxalone The risk or severity of adverse effects can be increased when Metaxalone is combined with Pancuronium. Magnesium cation The therapeutic efficacy of Pancuronium can be increased when used in combination with Magnesium cation. Nicotine The risk or severity of adverse effects can be increased when Nicotine is combined with Pancuronium. Bufylline The pancurknio efficacy of Pancuronium can be decreased when used in combination with Bufylline. Hypoxanthine The therapeutic efficacy of Pancuronium can be decreased when used in combination with Hypoxanthine.

Orphenadrine Pancuronium may increase the central nervous system depressant CNS depressant activities of Orphenadrine. Cyclobenzaprine The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined bromhro Pancuronium. Related Posts

IBICO ROJAS PDF

PANCURONIO ASTRAZENECA

.

LAPORAN INTERIM MH370 PDF

Principio Activo

.

Related Articles